Search

Your search keyword '"Pariente JL"' showing total 4 results
Start Over Author "Pariente JL" Topic carcinoma, transitional cell
4 results on '"Pariente JL"'

1. [Urothelial tumors].

Author

Irani J, Bernardini S, Bonnal JL, Coloby P, Colombel M, Davin JL, Laurent G, Lebret T, Maidenberg M, Mazerolles C, Pariente JL, Pfister C, Roy C, Saint F, and Theodore C

Subjects
Carcinoma, Transitional Cell classification, Female, Humans, Kidney Neoplasms classification, Male, Neoplasm Staging, Records, Ureteral Neoplasms classification, Urinary Bladder Neoplasms classification, Carcinoma, Transitional Cell diagnosis, Carcinoma, Transitional Cell therapy, Kidney Neoplasms diagnosis, Kidney Neoplasms therapy, Ureteral Neoplasms diagnosis, Ureteral Neoplasms therapy, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms therapy
Published
2004

2. [Upper urinary tract tumor: conservative treatment of localized forms].

Author

Irani J, Saint F, Bonnal JL, Mazerolles C, Theodore C, Lebret T, Pariente JL, Pfister C, Maidenberg M, Colombel M, Coloby P, and Davin JL

Subjects
Combined Modality Therapy, Humans, Carcinoma, Transitional Cell therapy, Kidney Neoplasms therapy, Ureteral Neoplasms therapy
Published
2003

3. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.

Author

Pariente JL, Bordenave L, Jacob F, Gobinet A, Leger F, Ferriere JM, and Le Guillou M

Subjects
Aged, Female, Humans, Keratin-19, Keratins, Male, Middle Aged, Prospective Studies, Reproducibility of Results, Antigens, Neoplasm urine, Biomarkers, Tumor urine, Carcinoma, Transitional Cell diagnosis, Carcinoma, Transitional Cell urine, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms urine
Abstract

Purpose: We evaluated CYFRA 21-1, an immunoradiometric assay, developed to detect soluble cytokaratin 19 fragment, for its diagnostic performance in bladder transitional cell carcinoma as well as its analytical performance., Materials and Methods: We assessed CYFRA 21-1 in the serum and urine of 182 patients, including 66 with bladder transitional cell carcinoma (group 1), 66 with another urological pathology (group 2) and 50 free of urothelial disease (group 3). The power of urinary CYFRA as a diagnostic test for bladder transitional cell carcinoma was evaluated by receiver operating characteristics curve analysis. Analytical performance was assessed by determining intra-assay and interassay precision, and accuracy by dilution testing and recovery of supplemented analyte., Results: Mean urinary CYFRA plus or minus standard deviation was 154.39+/-49.00, 22.6+/-8.9 and 2.40+/-0.14 ng./ml. in groups 1 to 3, respectively (significantly different). Receiver operating characteristics curve analysis revealed optimal 96.9% sensitivity and 67.2% specificity for a threshold value of 4 ng./ml. Analytical determination showed that intra-assay and interassay precision provides a satisfactory coefficient of variation. The assay for accuracy had acceptable recovery in diluted samples as well as in those with supplemented analyte., Conclusions: The urinary immunoradiometric CYFRA 21-1 assay performs well analytically. Urinary CYFRA 21-1 is a useful marker for diagnosing transitional cell carcinoma and provides sensitivity in low grade disease.

Published
2000

4. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.

Author

Pariente JL, Bordenave L, Michel P, Latapie MJ, Ducassou D, and Le Guillou M

Subjects
Aged, Biomarkers, Tumor blood, Carcinoma, Transitional Cell blood, Female, Humans, Keratins blood, Male, Middle Aged, ROC Curve, Sensitivity and Specificity, Urinary Bladder Neoplasms blood, Biomarkers, Tumor urine, Carcinoma, Transitional Cell urine, Immunoradiometric Assay, Keratins urine, Urinary Bladder Neoplasms urine
Abstract

Purpose: CYFRA 21-1, an immunoradiometric assay developed for the detection of a soluble cytokeratin 19 fragment, is evaluated for its diagnostic performance in urine of patients with transitional cell carcinoma., Materials and Methods: CYFRA 21-1 was investigated in serum and urine of 128 patients, including 48 with bladder transitional cell carcinoma (group 1), 44 with other urological pathological conditions (group 2) and 36 free of urothelial disease (group 3). Urinary cytopathology was also performed., Results: Mean urinary CYFRA was 123.5 +/- 53, 11.9 +/- 4.8 and 2.3 +/- 0.2 ng./ml. for groups 1 to 3, respectively, and was significantly different. From the receiver operating characteristics curve, the optimal combination of 96% sensitivity and 74% specificity was determined for a threshold value of 4 ng./ml. while overall cytopathology sensitivity was 43%., Conclusions: Urinary CYFRA 21-1 may be a useful marker for diagnosing transitional cell carcinoma.

Published
1997

Catalog

Books, media, physical & digital resources
See catalog results